Document Classification

Section Type: RESULTS

Text: The ACR20 response at week 12 was 39 % in the placebo group, 43 % in the 100 mg twice daily group (difference and 95 % CI compared with placebo, 4. 5 (-14. 1 to 23. 1) ; p = 0. 62) and 52 % in the 200 mg once daily group (13. 0 (-5. 8 to 31. 8) ; p = 0. 17) in the intention-to-treat population, and 30 % in the placebo group, 44 % in the 100 mg twice daily group (14. 4 (-5. 9 to 34. 8) ; p = 0. 17), and 56 % in the 200 mg once daily group (25. 8 (5. 3 to 46. 4) ; p = 0. 01) in the prespecified population of patients satisfying CRP and joint count eligibility criteria at the screening and day 1 (predose) visits.